Medizinische Klinik II (Hämatologie/Onkologie, Rheumatologie, Infektiologie, Therapie der HIV-Erkrankung)
3.3. Forschung
3.3.2. Forschungsprojekte Pathogeneseforschung
Arthritis (Prof. Dr. H. Burkhardt, Dr. B. Böhm)
Genetische Faktoren der Suszeptibilität und Erkrankungsschwere bei der rheumatoiden Arthritis und Psoriasis(arthritis) (Kooperation: Prof. Dr. A. Reis, FAU Erlangen-Nürnberg; Europäisches Consortium zur Psoriasisarthritis-Genetik (Page Consortium: Manchester/UK, Leeds/UK, Bath/UK, Dublin/Irland, Umea/Schweden, Rom/Italien, Leuwen/Belgien)
Bedeutung der Autoimmunität gegen gelenkspezifische Antigene (Kollagen Typ II) in der Pathogenese der rheumatoiden Arthritis (Kooperation: Prof. Dr. R. Holmdahl, Karolinska-Institut/Schweden)
Die pathogenetische Rolle des Transkriptionsfaktors NF-kB für arthritische Entzündungsprozesse Möglichkeiten und Risiken einer therapeutischen NF-kB-Inhibition (Kooperation: Prof. Dr. R. Voll, Freiburg)
Osteoarthritis (Dr. B. Böhm)
Die Pathogenetische Bedeutung der Disintegrin-Metalloproteinase ADAM15 für den Knorpelmetabolismus im Rahmen der Osteoarthritis
Systemische Sklerose (Dr. M. Köhm, Prof. Dr. H. Burkhardt)
Modulation des Lysophospholipidsignalling zur therapeutischen Beeinflussung der systemischen Sklerose (Kooperation: Prof. H. Radeke, Insitut für Pharmakologie, Goethe-Universität Frankfurt) Klinische Forschung
Therapieforschung (Dr. F. Behrens, Dr. M. Köhm, Prof. Dr. H. Burkhardt)
Im Jahre 2013 wurden 30 klinische Studien der Phasen Ib-IV in den Indikationsgebieten rheumatoide Arthritis, Psoriasisarthritis, Spondyloarthopathiden, Systemischer Lupus erythematosus und Sklerodermie durchgeführt. In 12 der multizentrischen Studien stellte die Rheumatologie in Frankfurt den Leiter der klinischen Prüfung in Deutschland.
Etablierung neuer prädiktiver Labormarker [BMBF-gefördertes ArthroMark-Konsortium: Kooperation mit Prof. Dr. G.R. Burmester (Berlin) und Prof. Dr. H. Schulze-Koops (München)] und klinischer Outcome-Parameter für die Rheumatoide Arthritis (Dr. Behrens, Prof. Dr. Burkhardt).
Psoriasis-Arthritis (Dr. Frank Behrens, Dr. M. Köhm)
Ziel: Analyse von Verlauf und Therapieeffizienz anhand großer multizentrischer Patientenkohorten.
Organisation eines Europäischen Forschungskonsortiums zur Genetik der Psoriasisarthritis (PAGEConsortium). Im Jahr 2013 wurde eine multizentrische Studie mit Förderung durch die Fa.
Pfizer zur Frühdiagnostik der Psoriasis Arthritis mittels eines neuartigen fuoreszentoptischen Bildgebungsverfahrens (Xiralite®) initiiert (IIT, Initiator und Studienleter: Dr. F. Behrens).
Sklerodermie (Dr. M. Köhm, Dr. F. Behrens)
Analyse von Verlauf und Therapieeffizienz bei Systemischer Sklerose 4. Wissenschaftliche Veröffentlichungen der Medizinische Klinik II
Originalarbeit
1. Allwinn R, Bickel M, Lassmann C, Wicker S, Friedrichs I (2013) "Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?". Med Microbiol Immunol, 202 (2): 125-30 2. Alpermann T, Kern W, Schnittger S, Schmid C, Kreuzer KA, Serve H, Pielken HJ, Schmitz N,
Wendtner CM, Haferlach C, Haferlach T (2013) Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.
LEUKEMIA RES, 37 (2): 197-200
3. Anastassiadis K, Schnütgen F, von Melchner H, Stewart AF (2013) Gene targeting and site-specific recombination in mouse ES cells. METHOD ENZYMOL, 533: 133-55
4. Antiretroviral Therapy Cohort Collaboration (ART-CC), Shepherd BS, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JAC, Sterling TR (2013) Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS, 27 (8): 1321-9
5. Apel M, Uebe S, Bowes J, Giardina E, Korendowych E, Juneblad K, Pasutto F, Ekici AB, McManus R, Ho P, Bruce IN, Ryan AW, Behrens F, Böhm B, Traupe H, Lohmann J, Gieger C, Wichmann HE, Padyukov L, Fitzgerald O, Alenius GM, McHugh NJ, Novelli G, Burkhardt H, Barton A, Reis A, Hüffmeier U (2013) Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. ARTHRITIS RHEUM-US, 65 (5): 1224-31
6. Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JHF, Ruthardt M, Ottmann OG (2013) Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia. PLoS One, 8 (11): e80070
7. Behrens F, Köhm M (2013) [Personalized medicine in cytokine-targeted therapy]. Z RHEUMATOL, 72 (1): 41-8
8. Behrens F, Finkenwirth C, Pavelka K, Štolfa J, Šipek-Dolnicar A, Thaçi D, Burkhardt H (2013) Leflunomide in psoriatic arthritis: results from a large European prospective observational study.
ARTHRIT CARE RES, 65 (3): 464-70
9. Behrens F, Tony HP, Alten R, Kleinert S, Scharbatke EC, Köhm M, Gnann H, Tams J, Greger G, Burkhardt H (2013) Development and validation of a new disease activity score in 28 joints-based treatment response criterion for rheumatoid arthritis. ARTHRIT CARE RES, 65 (10):
1608-16
10. Bergmann L, Goebell PJ, Kube U, Kindler M, Herrmann E, Janssen J, Schmitz J, Weikert S, Steiner G, Jakob A, Staehler MD, Steiner T, Overkamp F, Albrecht M, Guderian G, Doehn C (2013) Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study. ONKOLOGIE, 36 (3): 95-100
11. Bickel M, Lassmann C, Wieters I, Doerr HW, Herrmann E, Wicker S, Brodt HR, Stephan C, Allwinn R, Jung O (2013) Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls. HIV CLIN TRIALS, 14 (4):
175-81
12. Bickel M, Khaykin P, Stephan C, Schmidt K, Buettner M, Amann K, Lutz T, Gute P, Haberl A, Geiger H, Brodt H, Jung O (2013) Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV MED, 14 (10): 633-8
13. Bickel M, Marben W, Betz C, Khaykin P, Stephan C, Gute P, Haberl A, Knecht G, Wolf T, Brodt HR, Geiger H, Herrmann E, Jung O (2013) End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. HIV MED, 14 (3): 127-35
14. Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM, INSIGHT SMART Study Group (2013) Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS One, 8 (2): e56249
15. Böhm BB, Freund I, Krause K, Kinne RW, Burkhardt H (2013) ADAM15 adds to apoptosis resistance of synovial fibroblasts by modulating focal adhesion kinase signaling. ARTHRITIS RHEUM-US, 65 (11): 2826-34
16. Braulke F, Jung K, Schanz J, Götze K, Müller-Thomas C, Platzbecker U, Germing U, Brümmendorf TH, Bug G, Ottmann O, Giagounidis AAN, Stadler M, Hofmann WK, Schafhausen P, Lübbert M, Schlenk RF, Blau IW, Ganster C, Pfeiffer S, Shirneshan K, Metz M, Detken S, Seraphin J, Jentsch-Ullrich K, Böhme A, Schmidt B, Trümper L, Haase D (2013) Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study. LEUKEMIA RES, 37 (8): 900-6
17. Burkhardt U, Wojcik B, Zimmermann M, Klein J (2013) Phospholipase D is a target for inhibition of astroglial proliferation by ethanol. NEUROPHARMACOLOGY, 79C: 1-9
18. Burmeister T, Molkentin M, Schwartz S, Gökbuget N, Hoelzer D, Thiel E, Reinhardt R (2013) Erroneous class switching and false VDJ recombination: molecular dissection of t(8;14)/MYC-IGH translocations in Burkitt-type lymphoblastic leukemia/B-cell lymphoma. MOL ONCOL, 7 (4): 850-8
19. Capalbo G, Mueller-Kuller T, Koschmieder S, Klein HU, Ottmann OG, Hoelzer D, Scheuring UJ (2013) Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML. ONCOL REP, 30 (5): 2254-62
20. Capalbo G, Mueller-Kuller T, Koschmieder S, Klein HU, Ottmann OG, Hoelzer D, Scheuring UJ (2013) Characterization of ZC3H15 as a potential TRAF-2-interacting protein implicated in the NFκB pathway and overexpressed in AML. INT J ONCOL, 43 (1): 246-54
21. Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M, Schwerdtfeger R, Bethge WA, Basara N, Gramatzki M, Tischer J, Kolb HJ, Uharek L, Meyer RG, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C (2013) Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J CLIN ONCOL, 31 (26): 3259-71 22. Coskun E, Neumann M, Schlee C, Liebertz F, Heesch S, Goekbuget N, Hoelzer D, Baldus CD
(2013) MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia. LEUKEMIA RES, 37 (6): 647-56
23. DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG (2013) Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. LEUKEMIA, 27 (8): 1628-36
24. de Bruin AM, Demirel Ö, Hooibrink B, Brandts CH, Nolte MA (2013) Interferon-γ impairs proliferation of hematopoietic stem cells in mice. BLOOD, 121 (18): 3578-85
25. Di Perri G, Green B, Morrish G, Hill A, Faetkenheuer G, Bickel M, van Delft Y, Kurowski M, Kakuda T (2013) Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients. HIV CLIN TRIALS, 14 (3): 92-8
26. Eißmann M, Melzer IM, Fernández SBM, Michel G, Hrabě de Angelis M, Hoefler G, Finkenwirth P, Jauch A, Schoell B, Grez M, Schmidt M, Bartholomae CC, Newrzela S, Haetscher N, Rieger MA, Zachskorn C, Mittelbronn M, Zörnig M (2013) Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms.
ONCOGENE, 32 (20): 2586-91
27. Engelke M, Oellerich T, Dittmann K, Hsiao HH, Urlaub H, Serve H, Griesinger C, Wienands J (2013) Cutting edge: feed-forward activation of phospholipase Cγ2 via C2 domain-mediated binding to SLP65. J IMMUNOL, 191 (11): 5354-8
28. Feuermann Y, Kang K, Gavrilova O, Haetscher N, Jin Jang S, Hyun Yoo K, Jiang C, Gonzalez FJ, Robinson GW, Hennighausen L (2013) MiR-193b and miR-365-1 are not required for the development and function of brown fat in the mouse. RNA BIOL, 10 (12): 1807-14
29. Fiil BK, Damgaard RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S, Mailand N, Choudhary C, Komander D, Gyrd-Hansen M (2013) OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. MOL CELL, 50 (6): 818-30
30. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM (2013) Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
LEUKEMIA, 27 (1): 107-12
31. Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE (2013) MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. LEUKEMIA, 27 (1): 113-7
32. Giles FJ, Yin OQP, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM (2013) Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. EUR J CLIN PHARMACOL, 69 (4): 813-23
33. Gökbuget N (2013) How I treat older patients with ALL. BLOOD, 122 (8): 1366-75
34. Gökbuget N, Naumann R, Arbeitskreis AMG der DGHO (2013) [Application for academic multicenter studies at German ethical review boards]. ONKOLOGIE, 36 Suppl 2: 29-35
35. Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, Martinelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG (2013) A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. LEUKEMIA RES, 37 (9): 1100-6
36. Gueller S, Duenzinger U, Wolf T, Ajib S, Mousset S, Berger A, Martin H, Serve H, Bug G (2013) Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients.
TRANSPL INFECT DIS, 15 (4): 435-40
37. Hahn M, Dambacher S, Dulev S, Kuznetsova AY, Eck S, Wörz S, Sadic D, Schulte M, Mallm JP, Maiser A, Debs P, von Melchner H, Leonhardt H, Schermelleh L, Rohr K, Rippe K, Storchova Z, Schotta G (2013) Suv4-20h2 mediates chromatin compaction and is important for cohesin recruitment to heterochromatin. GENE DEV, 27 (8): 859-72
38. Harter PN, Dützmann S, Drott U, Zachskorn C, Hattingen E, Capper D, Gessler F, Senft C, Seifert V, Plate KH, Kögel D, Mittelbronn M (2013) Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model. NEUROPATHOLOGY, 33 (5): 515-25
39. Hartmann S, Jakobus C, Rengstl B, Döring C, Newrzela S, Brodt HR, Wolf T, Hansmann ML (2013) Spindle-shaped CD163+ rosetting macrophages replace CD4+ T-cells in HIV-related classical Hodgkin lymphoma. MODERN PATHOL, 26 (5): 648-57
40. Heesch S, Neumann M, Schwartz S, Bartram I, Schlee C, Burmeister T, Hänel M, Ganser A, Heuser M, Wendtner CM, Berdel WE, Gökbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD (2013) Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. ANN HEMATOL, 92 (6): 747-58
41. Heidler J, Fysikopoulos A, Wempe F, Seimetz M, Bangsow T, Tomasovic A, Veit F, Scheibe S, Pichl A, Weisel F, Lloyd KCK, Jaksch P, Klepetko W, Weissmann N, von Melchner H (2013) Sestrin-2, a repressor of PDGFRβ signalling, promotes cigarette-smoke-induced pulmonary emphysema in mice and is upregulated in individuals with COPD. DIS MODEL MECH, 6 (6):
1378-87
42. Heidler J, Strecker V, Csintalan F, Bleier L, Wittig I (2013) Quantification of protein complexes by blue native electrophoresis. METHODS MOL BIOL, 1033: 363-79
43. Himmelreich H, Rabenau HF, Rindermann M, Stephan C, Bickel M, Marzi I, Wicker S (2013) The management of needlestick injuries. Dtsch Arztebl Int, 110 (5): 61-7
44. Hoffmann C, Kohrs F, Sabranski M, Wolf E, Jaeger H, Wyen C, Siehl J, Baumgarten A, Hensel M, Jessen A, Schaaf B, Vogel M, Bogner J, Horst HA, Stephan C (2013) HIV-associated lung cancer: survival in an unselected cohort. Scand J Infect Dis, 45 (10): 766-72
45. Hoiczyk M, Grabellus F, Podleska L, Ahrens M, Schwindenhammer B, Taeger G, Pöttgen C, Schuler M, Bauer S (2013) Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age. INT J ONCOL, 43 (1): 23-8
46. Hoelzer D (2013) Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
CURR OPIN ONCOL, 25 (6): 701-6
47. Honold J, Thieme F, Zeuzem S, Serve H, Fichtlscherer S, Zeiher AM, Walcher F, Marzi I, Lehmann R (2013) [Characterization and economic impact of medical patients presenting at the emergency department of an university hospital]. DEUT MED WOCHENSCHR, 138 (27): 1401-5
48. Ihrig K, Fath B, Fuchs M, Hallek M, Marschner N, Naumann R, Röllig C, Saussele S, Tesch H, Gökbuget N (2013) [Focus on academic multicenter trials: impact of the German drug law on hematological/oncological therapy optimization trials]. ONKOLOGIE, 36 Suppl 2: 23-8
49. Ihrig K, Gökbuget N (2013) [QualiPRO: online database to facilitate study participation for investigators, study sites and coordinating centers]. ONKOLOGIE, 36 Suppl 2: 36-40
50. Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, Pagani C, Angelucci E, Terruzzi E, Levis A, Cassibba V, Mattei D, Gianfaldoni G, Scattolin AM, Di Bona E, Oldani E, Parolini M, Gökbuget N, Bassan R (2013) High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. HAEMATOL-HEMATOL J, 98 (11): 1718-25
51. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM (2013) Prediction of outcomes in patients with Ph+
chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. LEUKEMIA, 27 (4): 907-13
52. Jung O, Haack HS, Brodt HR, Grützmacher P, Geiger H, Amann K, Gröne HJ, Bickel M (2013) [Changing spectrum of renal disease in HIV infection]. DEUT MED WOCHENSCHR, 138 (38):
1887-91
53. Kaasch AJ, Rieg S, Kuetscher J, Brodt HR, Widmann T, Herrmann M, Meyer C, Welte T, Kern P, Haars U, Reuter S, Hübner I, Strauss R, Sinha B, Brunkhorst FM, Hellmich M, Fätkenheuer G, Kern WV, Seifert H, preSABATO study group (2013) Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study. Infection, 41 (5): 979-85
54. Kaiser MF, Heider U, Mieth M, Zang C, von Metzler I, Sezer O (2013) The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. EUR J HAEMATOL, 90 (4): 263-72
55. Kallenborn-Gerhardt W, Lu R, Syhr KMJ, Heidler J, von Melchner H, Geisslinger G, Bangsow T, Schmidtko A (2013) Antioxidant activity of sestrin 2 controls neuropathic pain after peripheral nerve injury. Antioxid Redox Signal, 19 (17): 2013-23
56. Kaufmann KB, Brendel C, Suerth JD, Mueller-Kuller U, Chen-Wichmann L, Schwäble J, Pahujani S, Kunkel H, Schambach A, Baum C, Grez M (2013) Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. MOL THER, 21 (3):
648-61
57. Kiderlen TR, Conteh M, Roll S, Seeling S, Weinmann S (2013) Cross-sectional study assessing HIV related knowledge, attitudes and behavior in Namibian public sector employees in capital and regional settings. PLoS One, 8 (9): e75593
58. Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Müller-Tidow C, Wörmann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Büchner T, German Acute Myeloid Leukemia Cooperative Group (AMLCG) (2013) Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. ANN HEMATOL, 92 (1): 41-52
59. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer
M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U, Gruppo Italiano Malattie Ematologiche dell'Adulto, German-Austrian Acute Myeloid Leukemia Study Group, Study Alliance Leukemia (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. NEW ENGL J MED, 369 (2): 111-21
60. Lösing M, Goldbeck I, Manno B, Oellerich T, Schnyder T, Bohnenberger H, Stork B, Urlaub H, Batista FD, Wienands J, Engelke M (2013) The Dok-3/Grb2 signal module attenuates Lyn-dependent activation of Syk in B cell antigen receptor microclusters. J BIOL CHEM, 288 ((4)):
2303-13
61. Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D (2013) Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J AM ACAD DERMATOL, 69 (5): 729-35
62. Meister M, Tomasovic A, Banning A, Tikkanen R (2013) Mitogen-Activated Protein (MAP) Kinase Scaffolding Proteins: A Recount. INT J MOL SCI, 14 (3): 4854-84
63. Miller K, Bergmann L, Gschwend J, Keilholz U, Kuczyk M, Wirth M (2013) [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. AKTUEL UROL, 44 (1):
45-9
64. Müller-Tidow C, Bug G, Lübbert M, Krämer A, Krauter J, Valent P, Nachbaur D, Berdel WE, Ottmann OG, Fritsch H, Munzert G, Garin-Chesa P, Fleischer F, Taube T, Döhner H (2013) A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
BRIT J HAEMATOL, 163 (2): 214-22
65. Najajreh Y, Khamaisie H, Ruimi N, Khatib S, Katzhendler J, Ruthardt M, Mahajna J (2013) Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines. MOL BIOL REP, 40 (3): 2205-13
66. Neumann M, Coskun E, Fransecky L, Mochmann LH, Bartram I, Sartangi NF, Heesch S, Gökbuget N, Schwartz S, Brandts C, Schlee C, Haas R, Dührsen U, Griesshammer M, Döhner H, Ehninger G, Burmeister T, Blau O, Thiel E, Hoelzer D, Hofmann WK, Baldus CD (2013) FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors. PLoS One, 8 (1): e53190
67. Neumann M, Heesch S, Schlee C, Schwartz S, Gökbuget N, Hoelzer D, Konstandin NP, Ksienzyk B, Vosberg S, Graf A, Krebs S, Blum H, Raff T, Brüggemann M, Hofmann WK, Hecht J, Bohlander SK, Greif PA, Baldus CD (2013) Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. BLOOD, 121 (23): 4749-52
68. Noda K, Dabovic B, Takagi K, Inoue T, Horiguchi M, Hirai M, Fujikawa Y, Akama TO, Kusumoto K, Zilberberg L, Sakai LY, Koli K, Naitoh M, von Melchner H, Suzuki S, Rifkin DB, Nakamura T (2013) Latent TGF-β binding protein 4 promotes elastic fiber assembly by interacting with fibulin-5. P NATL ACAD SCI USA, 110 (8): 2852-7
69. Oellerich T, Oellerich MF, Engelke M, Münch S, Mohr S, Nimz M, Hsiao HH, Corso J, Zhang J, Bohnenberger H, Berg T, Rieger MA, Wienands J, Bug G, Brandts C, Urlaub H, Serve H (2013) β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. BLOOD, 121 (19): 3889-99, S1-66
70. Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A, Kim DW, Fan X, Novick S, Giles FJ (2013) Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia. LEUKEMIA, 27 (6): 1411-3
71. Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhäuser M, Stadler M, Beelen D, Vucinic V, Burmeister T, Stelljes M, Faul C, Dreger P, Kiani A, Schäfer-Eckart K, Schwerdtfeger R, Lange E, Kubuschok B, Horst HA, Gramatzki M, Brück P, Serve H, Hoelzer D, Gökbuget N, Ottmann OG, GMALL Study Group (2013) Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. LEUKEMIA, 27 (6): 1254-62
72. Pfeiffer T, Schleuning M, Mayer J, Haude KH, Tischer J, Buchholz S, Bunjes D, Bug G, Holler E, Meyer RG, Greinix H, Scheid C, Christopeit M, Schnittger S, Braess J, Schlimok G, Spiekermann K, Ganser A, Kolb HJ, Schmid C (2013) Influence of molecular subgroups on
outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.
HAEMATOL-HEMATOL J, 98 (4): 518-25
73. Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönefeldt C, Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann WK, Ehninger G, Germing U, Haase D, Wermke M (2013) Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. LEUKEMIA, 27 (6): 1403-7
74. Poulsen SL, Hansen RK, Wagner SA, van Cuijk L, van Belle GJ, Streicher W, Wikström M, Choudhary C, Houtsmuller AB, Marteijn JA, Bekker-Jensen S, Mailand N (2013) RNF111/Arkadia is a SUMO-targeted ubiquitin ligase that facilitates the DNA damage response.
J CELL BIOL, 201 (6): 797-807
75. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R (2013) Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One, 8 (7): e68152
76. Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick R, Torti C, Dorrucci M, Günthard HF, Michalik C, Chrysos G, Castagna A (2013) Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. J INFECT DIS, 207 (5): 759-67 77. Reck M, Krzakowski M, Chmielowska E, Sebastian M, Hadler D, Fox T, Wang Q, Greenberg J,
Beckman RA, von Pawel J (2013) A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer. LUNG CANCER, 82 (3): 441-8
78. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ (2013) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. ANN ONCOL, 24 ((1)): 75-83
79. Reitter A, Stücker AU, Buxmann H, Herrmann E, Haberl AE, Schlößer R, Louwen F (2013) Prenatal ultrasound screening for fetal anomalies and outcomes in high-risk pregnancies due to maternal HIV infection: a retrospective study. INFECT DIS OBSTET GYNECOL, 2013: 208482 80. Rengstl B, Newrzela S, Heinrich T, Weiser C, Thalheimer FB, Schmid F, Warner K, Hartmann S, Schroeder T, Küppers R, Rieger MA, Hansmann ML (2013) Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells. P NATL ACAD SCI USA, 110 (51): 20729-34
81. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, on behalf of the Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381 ((9873)): 1203-10
82. Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, Serve H, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD, Schetelig J, Bornhäuser M, Ehninger G (2013) High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia:
results of the prospective randomized AML2003 trial. J CLIN ONCOL, 31 (17): 2094-102
83. Schmittel A, Sebastian M, Niederle N (2013) Zweitlinientherapie des kleinzelligen Lungenkarzinoms. ONKOLOGE, 19: 940-949
84. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G (2013)
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. LEUKEMIA, 27 (6): 1229-35
85. Schulz M, Bug G, Bialleck H, Serve H, Seifried E, Bönig H (2013) Leucodepletion for hyperleucocytosis--first report on a novel technology featuring electronic interphase management.
VOX SANG, 105 (1): 47-53
86. Schuette WHW, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M (2013) A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. CLIN LUNG CANCER, 14 (3): 215-23
87. Sebastian M, Heigener D, Alt-Epping B (2013) Palliativmedizinische Aspekte beim kleinzelligen Lungenkarzinom. ONKOLOGE, 19: 962-965
88. Sehnert B, Burkhardt H, Wessels JT, Schröder A, May MJ, Vestweber D, Zwerina J, Warnatz K, Nimmerjahn F, Schett G, Dübel S, Voll RE (2013) NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases. P NATL ACAD SCI USA, 110 (41): 16556-61
89. Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE (2013) Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J CLIN ONCOL, 31 (25): 3110-8
90. Stein S, Scholz S, Schwäble J, Sadat MA, Modlich U, Schultze-Strasser S, Diaz M, Chen-Wichmann L, Müller-Kuller U, Brendel C, Fronza R, Kaufmann KB, Naundorf S, Pech NK, Travers JB, Matute JD, Presson RG, Sandusky GE, Kunkel H, Rudolf E, Dillmann A, von Kalle C, Kühlcke K, Baum C, Schambach A, Dinauer MC, Schmidt M, Grez M (2013) From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease. HUM GENE THER CLIN DEV, 24 (2): 86-98 91. Stephan C, Bartha V, Herrmann E, von Hentig N, Khaykin P, Knecht G, Gute P, Brodt HR,
Stürmer M, Berger A, Bickel M (2013) Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy. Med Microbiol Immunol, 202 (2): 117-24
92. Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. CYTOTHERAPY, 15 (12): 1563-70
93. Uhrig M, Hassel JC, Schlemmer HP, Ganten MK (2013) Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST. ACAD RADIOL, 20 (4): 423-9
94. Uhrig M, Sedlmair M, Schlemmer HP, Hassel JC, Ganten M (2013) Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases. CANCER IMAGING, 13 (3): 306-13
95. Weinert BT, Iesmantavicius V, Wagner SA, Schölz C, Gummesson B, Beli P, Nyström T, Choudhary C (2013) Acetyl-phosphate is a critical determinant of lysine acetylation in E. coli.
MOL CELL, 51 (2): 265-72
96. Weinert BT, Schölz C, Wagner SA, Iesmantavicius V, Su D, Daniel JA, Choudhary C (2013) Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. CELL REP, 4 (4): 842-51
97. Wolf T, Goetsch U, Oremek G, Bickel M, Khaykin P, Haberl A, Bellinger O, Gottschalk R, Brodt HR, Stephan C (2013) Tuberculosis skin test, but not interferon-γ-releasing assays is affected by BCG vaccination in HIV patients. J INFECTION, 66 (4): 376-80
98. Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E, Becker S, Serve H, Huebner J (2013) Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J CANCER RES CLIN, 139 (3): 357-65
99. Zhou M, Meyer T, Koch S, Koch J, von Briesen H, Benito JM, Soriano V, Haberl A, Bickel M, Dübel S, Hust M, Dietrich U (2013) Identification of a new epitope for HIV-neutralizing
antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. EUR J IMMUNOL, 43 (2): 499-509
Review
1. Haberl A, Johnson M, Dominguez S, Miralles C, Monforte Ad, Anderson J (2013) The need for data on women living with HIV in Europe. ANTIVIR THER, 18 Suppl 2: 1-10
2. Krämer OH, Stauber RH, Bug G, Hartkamp J, Knauer SK (2013) SIAH proteins: critical roles in leukemogenesis. LEUKEMIA, 27 (4): 792-802
3. Shaid S, Brandts CH, Serve H, Dikic I (2013) Ubiquitination and selective autophagy. CELL DEATH DIFFER, 20 (1): 21-30
4. Stephan C, Hill A, Sawyer W, van Delft Y, Moecklinghoff C (2013) Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*. HIV MED, 14 (5): 284-92
Supplement
1. Haberl A, Reitter A (2013) How does HIV affect the reproductive choices of women of childbearing age? ANTIVIR THER, 18 (Suppl 2): 35-44
Editorial
1. Gökbuget N (2013) Akute lymphatische Leukämie des Erwachsenen (Teil II). KREBSMEDIZIN, 147-156
2. Gökbuget N (2013) Akute lymphatische Leukämie des Erwachsenen. KREBSMEDIZIN: 87-89 Fallbericht
1. Himmelreich H, Sarrazin CM, Stephan C, Rabenau HF, Marzi I, Wicker S (2013) [Early diagnosis of hepatitis C transmission after needlestick injury]. Unfallchirurg, 116 (7): 650-2 Interview
1. Brodt HR (2013) [Still far too many persons become infected also in Germany with HIV (interview by Peter Leiner)]. MMW FORTSCHR MED, 155 Suppl 1: 8-9
Letter
1. Raff T, Kaiser M, Gökbuget N, Lüschen S, Ritgen M, Trautmann H, Reutzel R, Hoelzer D, Kneba M, Brüggemann M (2013) Uncovering early, lineage-dependent effects of TPMT genotype in adult acute lymphoblastic leukemia by minimal residual disease. LEUKEMIA, 27 (4): 989-92
2. Schroeder T, Fröbel J, Cadeddu RP, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G (2013) Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. LEUKEMIA, 27 (9): 1910-3
3. Thol F, Kölking B, Hollink IHI, Damm F, van den Heuvel-Eibrink MM, Michel Zwaan C, Bug G, Ottmann O, Wagner K, Morgan M, Hofmann WK, Göhring G, Schlegelberger B, Krauter J, Ganser A, Heuser M (2013) Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. LEUKEMIA, 27 (3): 750-4
4. Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann WK, Krauter J, Kröger N, Ganser A, Heuser M (2013) SETBP1 mutation analysis in 944 patients with MDS and AML.
LEUKEMIA, 27 (10): 2072-5 Buchbeitrag
1. Brunnberg U (2013) Akute Leukemie. In: Jutta Hübner (Hg.) Onkologie interdisziplinär.
SCHATTAUER VERLAG, Stuttgart, 201-205
2. Gökbuget N, Holzer D (2013) Diagnosis and treatment of adult acute lymphoblastic leukemia. In:
Peter H. Wiernik, John M. Goldman, Janice P. Dutcher, Robert A. Kyle (Hg.) Neoplastic Diseases of the Blood. SPRINGER, New York, 331-354
3. Haberl A (2013) HIV und Frauen. In: Hoffmann C, Rockstroh J (Hg.) MEDIZIN FOKUS VERLAG, Hamburg, 500-503
Habilitation
1. Brandts C (2013) Konstitutive onkogene Aktivierung der PI3-Kinase- und STAT-Signaltransduktionswege in der malignen Transformation. Habilitation Universität Universität Frankfurt
Dissertation
1. Bossert B (2013) Vergleich von Effektivität und Nebenwirkungen von drei Erstlinien-Therapieregimen bei Patienten ab 59 Jahren aus der Frankfurter HIV-Kohorte. Dissertation Universität Frankfurt
2. Dubey A (2013) Der Einfluss des DEK/CAN-Fusionsproteins auf die Apoptose bei der t(6;9) positiven Akuten Myeloischen Leukämie. Dissertation Universität Frankfurt
3. Fuß BM (2013) Umstellung der antiretroviralen Therapie nach HIV-Resistenztestung:
Behandlungsverläufe und Risikofaktoren für virologisches Versagen in der Frankfurter HIV-Kohorte. Dissertation Universität Frankfurt
4. Heß S (2013) Graft-versus-Host Disease und Virus-DNA im Gastrointestinaltrakt: Eine retrospektive Kohortenanalyse von allogen transplantierten Patienten am Universitätsklinikum Frankfurt am Main. Dissertation Universität Frankfurt
5. Jesche RP (2013) Fieber bei Reiserückkehrern - Korrelation von Aufnahme- und Abschlussdiagnosen. Dissertation Universität Frankfurt